Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study

BACKGROUND: Vaniprevir is a potent macrocyclic hepatitis C virus (HCV) nonstructural protein 3/4A protease inhibitor. This phase III study evaluated the safety and efficacy of vaniprevir in combination with peginterferon alfa-2b and ribavirin (PR) for 24 weeks compared with PR alone for 48 weeks in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Norio, Nakamuta, Makoto, Takehara, Tetsuo, Kumada, Hiromitsu, Takase, Akiko, Howe, Anita Yee Mei, Ludmerer, Steven W., Mobashery, Niloufar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2015
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805724/
https://www.ncbi.nlm.nih.gov/pubmed/26403160
http://dx.doi.org/10.1007/s00535-015-1120-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805724/
https://www.ncbi.nlm.nih.gov/pubmed/26403160
http://dx.doi.org/10.1007/s00535-015-1120-x

Ejemplares similares